Lung cancer is an extraordinarily common, devastating and poorly understood disease responsible for ~160,000 deaths/year in the USA and 1.4 million deaths/year worldwide. Despite its prevalence and strikingly high mortality rates, the origins of the disease remain poorly understood and therapeutic approaches to treat lung cancer patients have proven disappointingly ineffective. The dismal prognosis for patients with advanced lung cancer emphasizes the urgent need for new chemotherapeutic approaches to treat this disease. The overarching, long-term goal of this research program is to aid development of rational therapeutic strategies to treat lung cancer patients, in full accord with the central mission of the National Cancer Institute. However, the immediate objective of this proposal is to explore the role of the Ras-activated RAF->MEK->ERK MAP kinase signal transduction pathway in the initiation, progression and therapy of lung cancer. This pathway is directly implicated in the aberrant physiology of lung cancer cells due to the prevalence of mutations in genes encoding the EGF receptor, KRAS or BRAF observed in primary patient specimens and human lung cancer derived cell lines. The central hypothesis of this grant proposal is that oncogenic KRasG12D or BRafV600E can initiate and maintain tumorigenesis in mouse models of human lung cancer through activation of the RAF->MEK->ERK pathway. Consequently we shall use genetically engineered KRasLSL and BRafCA mice, in which oncogene expression is initiated in the lung epithelium by infection with an adenovirus expressing Cre recombinase, to conduct an in-depth exploration of the role of oncogenic KRasG12D or BRafV600E in lung tumor initiation, progression and therapy.
In Aim 1 we will conduct a head-to-head comparison between KRasG12D- and BRafV600E-induced lung tumorigenesis to determine why the former progresses to adenocarcinoma while the latter does not. Next, to test the importance of RAF->MEK->ERK signaling downstream of KRasG12D-induced lung tumorigenesis, we will test the anti-tumor effects of potent, specific and selective pharmacological inhibitors of either RAF (SB590885) or MEK1/2 (PD0325901) using the KRasLSL mouse model of lung tumorigenesis.
In Aim 2 we will test the hypothesis that the loss of the Ink4a/Arf, Pten or Trp53 tumor suppressor genes can influence the response of KRasG12D- or BRafV600E-induced lung tumors to pharmacological inhibition of RAF or MEK using mice, and human and mouse lung cancer derived cell lines. Finally, in Aim 3, we will utilize our recently derived BRafFA mice, in which oncogenic BRafV600E expression is initiated by Flp recombinase, to assess how temporal dissociation of oncogene activation and tumor suppressor gene silencing influences tumor initiation, progression and senescence. Although this proposal is focused primarily on studies of the role of tumor suppressor and oncogene action on tumor biology and on mechanisms of drug response in mouse models of lung cancer, this research has potentially important translational significance in the design and evaluation of new targeted strategies to treat lung cancer patients.

Public Health Relevance

Lung cancer is a remarkably common, devastating and poorly understood disease responsible for ~160,000 deaths/year in the USA and 1.4 million deaths/year worldwide. Here, we propose the use of sophisticated genetically engineered mouse models of cancer and new targeted pharmacological inhibitors of cell signaling pathways to explore the importance of tumor suppressors and oncogenes in lung cancer initiation, progression and therapy. The long-term goal of these experiments is the development of new and rationally designed strategies to more effectively treat lung cancer patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Jhappan, Chamelli
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Charles, Roch-Philippe; Silva, Jillian; Iezza, Gioia et al. (2014) Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res 12:979-86
Deuker, Marian M; McMahon, Martin (2014) Cancer biology: Enzyme meets a surprise target. Nature 510:225-6
Holderfield, Matthew; Deuker, Marian M; McCormick, Frank et al. (2014) Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 14:455-67
Silva, Jillian M; McMahon, Martin (2014) The fastest Western in town: a contemporary twist on the classic Western blot analysis. J Vis Exp :e51149
McFadden, David G; Vernon, Amanda; Santiago, Philip M et al. (2014) p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A 111:E1600-9
Juan, Joseph; Muraguchi, Teruyuki; Iezza, Gioia et al. (2014) Diminished WNT -> ?-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev 28:561-75
Trejo, Christy L; Green, Shon; Marsh, Victoria et al. (2013) Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Res 73:6448-61
Strohecker, Anne M; Guo, Jessie Yanxiang; Karsli-Uzunbas, Gizem et al. (2013) Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 3:1272-85
Li, Chun-Ying; Cha, Wanghee; Luder, Hans-Ulrich et al. (2012) E-cadherin regulates the behavior and fate of epithelial stem cells and their progeny in the mouse incisor. Dev Biol 366:357-66
Trejo, Christy L; Juan, Joseph; Vicent, Silvestre et al. (2012) MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res 72:3048-59

Showing the most recent 10 out of 12 publications